Filing Flows › OptimizeRx (OPRX) › Q1 2026 › vs Q1 2025
OptimizeRx (OPRX) Q1 2026 vs Q1 2025 (year over year)
OptimizeRx's revenue fell $2.1M (-10%) from $21.9M in Q1 2025 to $19.8M in Q1 2026.
OptimizeRx, Q1 2026: revenue $19.8M (-10% year over year), operating margin 2.0%, net loss $495K, operating cash flow −$467K. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.8M | $21.9M | −$2.1M | -10% |
| Income tax benefit | $149K | $1.1M | −$924K | -86% |
| Net loss | $495K | $2.2M | −$1.7M | -77% |
| Costs & expenses | $20.5M | $25.2M | −$4.7M | -19% |
| Operating costs | $19.4M | $24.0M | −$4.6M | -19% |
| Interest & other, net | $1.0M | $1.2M | −$130K | -11% |
| Research & development | $3.4M | $3.3M | $150K | +5% |
| Sales & marketing | $4.7M | $5.0M | −$256K | -5% |
| General & admin | $3.5M | $4.6M | −$1.0M | -23% |
| Other operating costs | $2.9M | $2.7M | $240K | +9% |
| Operating cash sources | $3.4M | −$1.2M | $4.6M | — |
| Depreciation & amortization | $1.1M | $1.1M | −$30K | -3% |
| Share-based compensation | $1.8M | $1.6M | $270K | +17% |
| Cash used in operations | $467K | −$3.9M | $4.3M | — |
| Net loss absorbed | $495K | $2.2M | −$1.7M | -77% |
| Working capital & other | $2.9M | −$3.4M | $6.3M | — |
Questions
How much did OptimizeRx's revenue grow year over year in Q1 2026?
OptimizeRx's revenue fell $2.1M (-10%) from $21.9M in Q1 2025 to $19.8M in Q1 2026.